Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more ...

Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Western drugmakers, investors increasingly aim to acquire Chinese compounds.

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Pfizer has struck a high-stakes deal with 3SBio to license SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside ...

Pfizer on Tuesday announced a cancer drug licensing deal with Chinese biotech 3SBio that includes a $1.25 billion upfront ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

The company bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...